implantation for articular cartilage defects. Clinical trials are underway to assess the use of stem cells in the treatment of heart disease. Likewise, preclinical and early clinical trials have highlighted the potential of stem cells for the treatment of diabetes, spinal cord injury and other central nervous system disorders (e.g. cerebral palsy and Parkinson's disease). Adult stem cells per se display very few complications, while the major potential risk associated with pluripotent cells is tumorigenicity.
There are several essential pillars to a successful cell therapy environment. These include a robust regulatory environment, quality assurance and accreditation. Also essential is an appropriate informed consent process, in which the benefits and potential side-effects of the therapy are clearly laid out. The legal requirements for tissue donation should also be clearly articulated to curtail possible trade and trafficking in human tissue.
What is the current situation in SA? Hematopoietic stem cell transplantation has been practised successfully in the country for several decades. Sources of stem cells mainly include bone marrow and peripheral blood, which may be autologous, or allogeneic. Umbilical cordblood-derived stem cells have also been used. SA also has a Bone Marrow Registry (SABMR) [2] that sources stem cells from unrelated voluntary donors for allogeneic transplantation. SA does not at present have a public cord-blood stem cell bank. In SA private cord-blood banking is offered by Netcells Biosciences and Cryo-Save South Africa. The difference between public and private banks is essentially the difference between an anonymous donation versus storage for private use: in the case of a public bank, cord blood is donated altruistically and is available for any histocompatible patient who needs an allogeneic transplant, while in the case of a private bank, the bank is paid to store cord-blood stem cells for autologous use or for use by next-of-kin. Private banks are contractually obliged to return the stored cells on request and at the bank's expense, exclusively to the owner (or a contractually determined beneficiary).
Human tissue legislation -objectives
Human tissue legislation broadly aims to protect the individual from harmful and unethical practices, while at the same time giving effect to the individual's right to autonomy and self-determination as this relates to decisions regarding the use of his or her own stem cells. The Constitution directs in section 39(2) that, when interpreting legislation, every court, tribunal or forum 'must promote the spirit, purport or objects of the Bill of Rights' , which in essence refers to the promotion of the public interest. The legislative process should strive to further the goals and objectives of the Constitution, which includes the promotion of human rights. For example, all South Africans should be able to share in the benefits arising from advances in medical science in an equitable and sustainable manner.
In developing legislation, objectives should be realistic and every effort should be made to ensure simplicity and clarity. In the context of the regulation of human tissue, legislation should be enabling and not be unduly restrictive so as to avoid stifling basic and clinical research and biotechnological innovation. If legislation includes sanctions, these should be unambiguous and legally justified. Those affected by any legislative restriction or penalty should be aware of the limitations and the consequences of any transgressions.
In order to achieve all of the above, South African-specific objectives need to be combined with international best practice and the involvement of local professional societies needs to be encouraged.
The South African Constitution
The Constitution of the Republic of South Africa, 1996, enshrines the values on which SA's constitutional democracy is founded. Chapter 2 of the Constitution (the Bill of Rights) contains the fundamental rights and freedoms. These rights may be limited by section 36 of the Constitution and are therefore not absolute. However, some of the rights that are specifically relevant in the context of the regulation of human tissue are the right to equality (section 9); the right to human dignity (section 10); the right to life (section 11); the right to privacy (section 14); the right of a person to freedom and security, which includes the right to security in and control over one's body and the right not to be subjected to medical or scientific experiments without informed consent (section 12); and the right of access to healthcare (section 27).
The following four principles, espoused by Beauchamp and Childress [3] provide a very useful framework for the consideration of medical ethics issues generally, namely:
• Autonomy, which includes respecting the patient's right to make decisions regarding her or his treatment. In this respect, consent always needs to be informed in the broadest sense with the patient being made aware of both the benefits and possible side-effects. The importance of an adequate Materials Transfer Agreement cannot be overemphasised, particularly in a country in which discrimination and benefit sharing have not been adequately addressed. Both autonomy and self-determination are recognised in the provisions regarding the right to bodily and psychological integrity, the right to privacy and the right to life. Human dignity, inextricably linked to health and life as a constitutional value, informs the interpretation of all other rights. [4] • Beneficence, the moral foundation on which the medical profession rests, includes a consideration of the benefits of treatment against risks and costs. It is also critical that the therapy being applied has previously been shown to be of benefit in patients with a similar condition, preferably through the avenue of well-controlled and appropriately designed clinical trials. Beneficence finds expression in the provisions of the Constitution that relate to the right to life and the right of access to healthcare services (within the limits of available resources). • Non-maleficence, which implies avoiding the causation of harm.
The harm should not be disproportionate to the benefits of the treatment. Early phase clinical trials (phases I and II) are required to establish the facts. This principle is expressed, for example, in the constitutional right not to be subjected to medical or scientific experiments without informed consent. • Justice and fairness, which require that benefits, risks and costs be distributed fairly. In the SA context, distributive justice will ensure that all South Africans will benefit from cell-based therapy. The right to equality and the right of access to healthcare services embody these principles.
These four principles are not only aligned with the Constitution, but if observed, will promote the realisation of the rights articulated therein, in addition to assisting in deterring possible criminal and unprofessional conduct in the context of stem cell research and therapy.
The Acts
Principally The NHA was assented to by the President on 18 July 2004 and came into force on 2 May 2005. However, the main section dealing with human tissues, namely Chapter 8 entitled the 'Control of use of blood, blood products, tissue and gametes in humans' , was only fully enacted as recently as 2 March 2012. As mentioned previously, matters pertaining to human tissues were previously legislated under the Human Tissue Act 65 of 1983, which was repealed with the enactment of the final sections of the NHA in 2012. [5] Chapter 8 of the NHA covers seven areas that are relevant to human tissues. These include: 'Tissue' is defined in section 1 of the NHA as 'human tissue, and includes flesh, bone, a gland, an organ, skin, bone marrow or body fluid, but excludes blood or a gamete' . An organ is defined in the same section as 'any part of the human body adapted by its structure to perform any particular vital function, including the eye and its accessories' . Suggested alternatives to these definitions are provided in Table 2 .
With regard to human cloning, the manipulation of any genetic material for the purpose of reproductive cloning of a human being is prohibited in terms of section 57(1) of the NHA, read together with section 57(6)(a). Cloning for therapeutic purposes is provided for in section 57(2) of the Act, read together with section 57(6)(b).
These definitions (i.e. 'reproductive cloning of a human being' and 'therapeutic cloning') are however problematic; alternatives are provided in Table 3 . A person contravening or failing to comply with this section is guilty of an offence and is liable, on conviction, to a fine or to imprisonment for a period not exceeding 5 years or to both a fine and such imprisonment (section 57 (5)).
Research on stem cells and zygotes which are not more than 14 days old may in terms of section 57(4) of the NHA only be conducted with the permission of the Minister and under certain conditions, namely that the research shall be documented and prior consent be obtained from the donor of such stem cells or zygotes.
Section 56 of the NHA ('Use of tissue, blood, blood products or gametes removed or withdrawn from living persons') provides that that the removal or withdrawal of stem cells (excluding umbilical cord progenitor cells) from a living person for medical or dental purposes requires ministerial authorisation. Specific restrictions regarding the removal of tissue, blood, blood products or gametes from living persons are found in section 56(2), which states as follows: This implies that HSC transplantation, which has been practised for several decades in SA, requires ministerial authorisation, as will all future applications of stem cell therapy requiring removal or withdrawal of stem cells from a living person. The exception appears to be umbilical cord progenitor cells, which implies that other cells harvested from cord blood (i.e. earlier primitive stem cells that are not progenitors and non-haematopoietic stem cells) will also require ministerial authorisation. The legislator's reason for making this distinction is not apparent. On the other hand, no mention is made of the requirement for ministerial approval in the Regulations Relating to the Use of Human Biological Material, which provide that biological material -which includes progenitor stem cells [6] -may be removed or withdrawn from living adult persons with their informed consent. [7] It is suggested that section 56(2)(a)(iv) above be changed to refer only to 'embryonic or fetal tissue' .
In addition to Chapter 8, several important areas are covered by Chapter 9 of the NHA which deals with 'National Health Research and Information' . Section 71, for example, entitled 'Research on or experimentation with human subjects' , states that all research conducted on minors (e.g. persons younger than 18 years) for non-therapeutic purposes requires ministerial authorisation (section 71(3)), whereas in the instance of research for therapeutic purposes, ministerial authorisation is apparently not required (section 71(2)), but only the consent of the parent or guardian, or the relevant child if he or she is capable of understanding. The rationale behind the requirement for ministerial authorisation where research or experimentation is to be conducted on a minor for non-therapeutic purposes (not benefiting the specific minor), but not for therapeutic purposes, is unclear. The Minister may not authorise such research for non-therapeutic purposes involving a minor if, among others, the research poses a 'significant risk' to the health of the minor, or 'some risk' , though there is the likelihood of 'some benefit' to the minor (section 71(3)(b)). Paradoxically, it would seem that ministerial authorisation for the latter would be important. The purpose of this is clearly to protect minors from unscrupulous research practices, but in the absence of a definition of what 'significant risk' or 'some risk' are, which differ from the requirements stated in the national ethics guidelines, [8] this adds more confusion. [9] 
Regulations
Various sets of regulations relating to Chapter 8 of the NHA came into effect on 2 March 2012 (Table 4) . These include regulations relating to the general control of human bodies, tissue, blood, blood products and gametes; [10] the use of human biological material; [11] blood and blood products; [12] import and export of human tissue, blood, blood products, cultured cells, stem cells, embryos, fetal tissue, zygotes and gametes; [13] stem cell banks [14] and tissue banks. [15] With regard to some of these sets of regulations that relate to human tissue, there is a degree of redundancy and overlap. Definitions, for example, are not harmonised, both between different regulations and relative to the NHA. In addition, there are at present no regulations regarding cell-based therapy, bio-banks or transplantation.
With regard to definitions, a cell is defined in Regulations Relating to the Artificial Fertilisation of Persons as 'the basic structural and functional unit in people and all living things and is a small container of chemical and water wrapped in a membrane' (Table 3 ). This definition is clearly wanting for detail, which is necessary in the modern setting of highly sophisticated technology. On the other hand, the regulations on the use of human biological material defines a cell as 'the smallest structural and functional unit of an organism, consisting of cytoplasm and a nucleus enclosed in a membrane in living things' , which is more appropriate.
Transgenic cells are defined in the Regulations Relating to the Use of Human Biological Material as cells being 'derived from a species other than human' . The universally accepted definition of cells derived from a species other than human is 'xenogeneic' . For example, one source [16] defines xenogeneic as 'derived or obtained from an organism of a different species, as a tissue graft' .
Transgenic on the other hand means an organism whose genome has been altered by the transfer of a gene or genes through recombinant DNA techniques from another species or breed using recombinant DNA techniques, e.g. transgenic mice. [17] It is understood that the foreign genes are in the transgenic animal's germ-cell DNA and so can be transmitted from one generation to the next. [18] Clearly this and other frankly incorrect definitions require urgent amendment.
Guidelines and standards
With regard to guidelines and standards, none have been officially published or endorsed by the National Department of Health in the human tissue field. As a result and in response to the need to provide clarity to professionals working in these fields, several professional bodies have established their own guidelines. These bodies are listed in Table 5 .
It should be noted, however, that national standards for cellular therapy product collection, processing, storage and distribution have been drafted and will hopefully be published in the near future. These standards do not include stem cell therapy per se, which would for now need to be covered in SA by the South African Stem Cell Transplantation Society standards. It is important that the drafting of all guidelines and standards be done in close alignment with national professional bodies, as well as international bodies such as the Foundation for the Accreditation of Cellular Therapy, [19] the Joint [20] and the American Association of Blood Banks.
[21] Any discussion on human tissue legislation (and in particular stem cells) needs to make a distinction between activities that involve altruistic donation of human material and those that result in commercial gain. Any commercial activity directly involving human material (including stem cells) that is provided on an altruistic basis by a voluntary donor should be run on a not-forprofit cost recovery basis with publicly accessible accountability of how resources are managed. Other activities that involve human stem cells directly or indirectly and that are not based on the principle of an altruistic donation should be permitted to run on a for-profit basis. This includes storage and manipulation of stem cells for individuals who pay for the service on a fee-for-service basis, as well as all related activities including but not limited to the development and manufacture of materials for tissue culture (equipment, plastic ware, reagents including growth factors) and medical devices (including those required for stem cell harvesting and purification). It is important to note that the NHA prohibits the sale of and trade in stem cells, as this would be tantamount to 'organ trafficking' even though a stem cell(s) is not an organ per se. Furthermore, an authorised institution may only receive payment in respect of the acquisition, supply, importation or export of stem cells.
Economic considerations
Although it is clear that a public cord-blood bank in which stem cells are altruistically donated must be a not-for-profit company run on the basis of cost-recovery, the indiscriminate application across the board of a not-for-profit rule in all matters pertaining to human tissues and stem cells, in particular, would severely stifle the rollout of stem cell therapies and related research in SA. The cell therapy industry is still in its infancy in this country, and preventing the establishment of for-profit companies would stifle the implementation of new cell therapy technologies as well as all future research activity into stem cells in the biotechnology sector. The latter is emphasised in the Bioeconomy strategy released in 2014 by the Department of Science and Technology.
[22] The therapeutic promise of stem cells has driven huge investment globally into the cell therapy industry. Without this investment, and the return it promises to bring to its investors, progress in the field would be significantly stunted. 
Conclusion
Legislation in its broadest sense should be seen as a permanent workin-progress requiring ongoing review. The importance of feedback from all sectors concerned including patients and their healthcare providers cannot be overemphasised. Legislation in its broadest sense is needed: • To ensure that pre-clinical studies and well controlled clinical trials have been conducted prior to introduction of cells into patients:
• to ensure that the purported therapeutic effect is real • to ensure that there are no serious side effects • To ensure that work involving material that will be (re)introduced into patients is conducted in an accredited institution under strictly controlled conditions.
The absence of appropriate legislation:
• Permits (and even encourages) the emergence of medically unsound and unethical practices that may be associated with the exploitation of emotionally vulnerable patients.
• Dissuades the transfer into SA of much-needed skilled individuals, intellectual property and foreign investment in the cell-therapy field.
In SA we have 'need' from the perspective of the patient, 'ability' from the perspective of the medical, scientific and business communities, and 'material' both from a research and therapeutic perspective. Legislation in SA in the human tissue field, and in stem cells in particular, is still in its infancy. This provides healthcare professionals and researchers with an opportunity to assist the legislator in drafting legislation that is both modern and appropriate to the diverse needs of the SA population. However, while legislation is necessary to protect patients and their healthcare providers, it should not be stifling or obstructive. With regard to clinical trials, these need to be registered with the Medicines Control Council (MCC) and would include any form of therapy that is unproven or experimental in nature. Protocols need to be examined by a registered institutional ethics committee (peer reviewed). Finally, patients should not have to pay for treatments that are unproven or experimental.
Based on the broad outline provided above and in mapping out the process ahead, it is recommended that:
• An oversight and coordinating committee be established, which includes government, academia and the private sector, to work with groups in each of the seven areas delineated above together with the legislator, to constantly monitor new developments in order to be able to be agile in response thereto.
• The current legislation be revised to close regulatory gaps, remove inaccuracies and redundancy and to ensure that all legislation is harmonised.
